Interplay Between Estrogen Signaling and Metabolic Biomarkers in Breast Cancer Progression

Rabab Adnan  Hamzah

doi:10.51699/cajmns.v7i3.3229

Authors

Rabab Adnan Hamzah Technical Institute of Babylon, AL-Furat Al-Awsat Technical University (ATU), Iraq

DOI:

https://doi.org/10.51699/cajmns.v7i3.3229

Keywords:

Estrogen receptor, Breast cancer, Insulin resistance, Leptin, Adiponectin

Abstract

Background: Breast cancer growth involves androgen and estrogen signaling and metabolism. Adipokines and insulin resistance modulate hormone sensitivity, invasion and growt. Aims of the study: This study aims to investigate the association between estrogen receptor pathway and metabolic factors in female patients with breast cancer, and their impact on the tumor characteristics and clinical outcomes. And to investigate the role of insulin resistance and adipokine (leptin and adiponectin) imbalance as a predictor of tumor. Methodology: A case–control study was conducted from April 2025 to February 2026 at an oncology center in Iraq, including 80 breast cancer patients and 30 matched healthy controls. Diagnosis was confirmed histopathologically, and staging followed the TNM system. ER status was assessed by immunohistochemistry (≥10% positivity). Blood samples were collected, centrifuged, and serum stored at −20°C. Glucose was measured enzymatically, while insulin, leptin, and adiponectin were analyzed using ELISA. HOMA-IR was calculated. Only newly diagnosed patients were included; those with metabolic or endocrine disorders were excluded. Result: Most patients were ≥50 years (57.5%) with grade II disease (45.0%) and 55.0% had early stage disease. 65.0% showed ER positivity. Biomarkers showed significant differences between patients and controls (p < 0.001) revealing insulin resistance and altered adipokines. Metabolic biomarkers were worse among ER-negative patients. ER level was negatively associated with tumor grade and stage, and biomarkers. Multivariate analysis revealed ER-negative status, HOMA-IR and leptin as indicators of disease progression, with adiponectin showing borderline significance. Conclusions: Loss of the estrogen receptor (ER) and metabolic dysfunction are key factors in the progression of breast cancer. Insulin resistance and overproduction of leptin stimulate tumor growth through the PI3K/Akt pathway, and decreased adiponectin levels diminish anti-proliferative activity increasing tumor inviveness.

References

J. Kim et al., “Global patterns and trends in breast cancer incidence and mortality across 185 countries,” Nature Medicine, vol. 31, no. 4, pp. 1154–1162, 2025.

Y. Zhang et al., “Global burden of female breast cancer: New estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN,” Journal of the National Cancer Center, vol. 5, no. 3, pp. 287–296, 2025.

N. Kim and K. E. Lukong, “Treating ER-positive breast cancer: A review of the current FDA-approved SERMs and SERDs and their mechanisms of action,” Oncology Reviews, vol. 19, p. 1564642, 2025.

S. Mazloomi, “Comparing clinical characteristics and outcomes of single versus double positive and negative hormone receptor breast tumors: Results from a 27-year follow-up study,” 2025.

C. Reytor-González et al., “Obesity and breast cancer: Exploring the nexus of chronic inflammation, metabolic dysregulation, and nutritional strategies,” Food and Agricultural Immunology, vol. 36, no. 1, p. 2521270, 2025.

A. Caturano et al., “Insulin resistance and cancer: Molecular links and clinical perspectives,” Molecular and Cellular Biochemistry, vol. 480, no. 7, pp. 3995–4014, 2025.

J. Ngugi Mwaura, “Natural product modulators of adipokine signaling: A new frontier in obesity-associated cancer therapy.”

G. H. Sakban et al., “Exploring biomarkers, adipokines, and cytokines in patients with colon cancer: A comparative study with healthy controls,” Regulatory Mechanisms in Biosystems, vol. 16, no. 3, p. e25150, 2025.

X. Ma, S. Yang, and D. Li, “New insights into adipokines and the tumor microenvironment in breast cancer,” Cancer Control, vol. 32, 2025.

J. Dong et al., “The impact of estrogen deficiency on liver metabolism: Implications for hormone replacement therapy,” Endocrine Reviews, vol. 46, no. 6, pp. 790–809, 2025.

A. Dehghani, “The immunoregulatory roles of ERα in breast cancer: Mechanisms, crosstalk, and therapeutic insights,” Journal of Cancer Prevention, vol. 31, no. 1, p. 1, 2026.

Y. Zhang et al., “Metformin and oncogenic pathways: Crosstalk between energy sensing and tumor progression,” Molecular and Cellular Probes, 2026.

S. Mazloomi, “Comparing clinical characteristics and outcomes of single versus double positive and negative hormone receptor breast tumors: Results from a 27-year follow-up study,” 2025.

N. McShane et al., “Hormone receptor positive breast cancer in young women: A review,” Journal of Surgical Oncology, vol. 131, no. 4, pp. 580–586, 2025.

Y. Karadeniz et al., “Comparison of triglyceride-glucose index and HOMA-IR in assessing insulin resistance in acromegaly: A case-control study,” Endokrynologia Polska, vol. 76, no. 4, pp. 442–449, 2025.

M. Mustari et al., “Triglyceride/high-density lipoprotein cholesterol ratio and triglyceride–glucose index: Potential cost-effective markers of insulin resistance in polycystic ovary syndrome,” Bangladesh Journal of Endocrinology and Metabolism, vol. 4, no. 3, pp. 164–170, 2025.

F. Namukasa Mugerwa, “The impact of hyperinsulinemia and hyperglycemia on cancer risk and progression in obese diabetics.”

A. Caturano et al., “Insulin resistance and cancer: Molecular links and clinical perspectives,” Molecular and Cellular Biochemistry, vol. 480, no. 7, pp. 3995–4014, 2025.

A. S. Neamah et al., “The potential role of targeting the leptin receptor as a treatment for breast cancer in the context of hyperleptinemia: A literature review,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 398, no. 4, pp. 3451–3466, 2025.

S. Modak et al., “A systematic review on leptin’s role in defining cancer: Special emphasis on immunomodulation, inflammation, and therapeutic interventions,” Genes & Immunity, vol. 26, no. 3, pp. 266–286, 2025.

M. Gaber et al., “Obesity increases DNA damage in the breast epithelium,” Breast Cancer Research, vol. 27, no. 1, p. 11, 2025.

Y. Liu et al., “Multidimensional risk impact of obesity on breast cancer incidence, treatment, and prognosis: Bariatric surgery,” International Journal of Obesity, 2026.

S. Loi et al., “Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: A randomized phase 3 trial,” Nature Medicine, vol. 31, no. 2, pp. 433–441, 2025.

F. Viehweger et al., “Estrogen receptor expression in human tumors: A tissue microarray study evaluating more than 18,000 tumors from 149 different entities,” Human Pathology, vol. 157, p. 105757, 2025.

W. Ren et al., “Comprehensive analysis of metabolism-related gene biomarkers reveals their impact on the diagnosis and prognosis of triple-negative breast cancer,” BMC Cancer, vol. 25, no. 1, p. 668, 2025.

E. W. Pierro et al., “TREM2 expressing macrophages are not associated with prognostic markers or metabolic syndrome in early stage ER positive breast cancer,” Scientific Reports, vol. 15, no. 1, p. 38888, 2025.

T. O. Lawal, B. A. Adeniyi, and G. B. Mahady, “Vitamins A and D and their combinations for breast and colorectal cancers: Analysis of the clinical, epidemiological, preclinical and transcriptomic data,” Pharmaceuticals, vol. 18, no. 11, p. 1684, 2025.

P. P. Strømland et al., “Effects of metformin on transcriptomic and metabolomic profiles in breast cancer survivors enrolled in the randomized placebo-controlled MetBreCS trial,” Scientific Reports, vol. 15, no. 1, p. 16897, 2025.

E. J. Houston and N. M. Templeman, “Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS,” Journal of Endocrinology, vol. 265, no. 2, 2025.